BACKGROUND: A decade after promulgation of treatment guidelines by the Brain Trauma Foundation (BTF), few studies exist that examine the application of these guidelines for severe traumatic brain injury (TBI) patients. These studies have reported both cost savings and reduced mortality. MATERIALS: We projected the results of previous studies of BTF guideline adoption to estimate the impact of widespread adoption across the United States. We used surveillance systems and national surveys to estimate the number of severely injured TBI patients and compared the lifetime costs of BTF adoption to the current state of treatment. RESULTS: After examining the health outcomes and costs, we estimated that a substantial savings in annual medical costs ($262 million), annual rehabilitation costs ($43 million) and lifetime societal costs ($3.84 billion) would be achieved if treatment guidelines were used more routinely. Implementation costs were estimated to be $61 million. The net savings were primarily because of better health outcomes and a decreased burden on lifetime social support systems. We also estimate that mortality would be reduced by 3,607 lives if the guidelines were followed. CONCLUSIONS: Widespread adoption of the BTF guidelines for the treatment of severe TBI would result in substantial savings in costs and lives. The majority of cost savings are societal costs. Further validation work to identify the most effective aspects of the BTF guidelines is warranted.
BACKGROUND: A decade after promulgation of treatment guidelines by the Brain Trauma Foundation (BTF), few studies exist that examine the application of these guidelines for severe traumatic brain injury (TBI) patients. These studies have reported both cost savings and reduced mortality. MATERIALS: We projected the results of previous studies of BTF guideline adoption to estimate the impact of widespread adoption across the United States. We used surveillance systems and national surveys to estimate the number of severely injured TBI patients and compared the lifetime costs of BTF adoption to the current state of treatment. RESULTS: After examining the health outcomes and costs, we estimated that a substantial savings in annual medical costs ($262 million), annual rehabilitation costs ($43 million) and lifetime societal costs ($3.84 billion) would be achieved if treatment guidelines were used more routinely. Implementation costs were estimated to be $61 million. The net savings were primarily because of better health outcomes and a decreased burden on lifetime social support systems. We also estimate that mortality would be reduced by 3,607 lives if the guidelines were followed. CONCLUSIONS: Widespread adoption of the BTF guidelines for the treatment of severe TBI would result in substantial savings in costs and lives. The majority of cost savings are societal costs. Further validation work to identify the most effective aspects of the BTF guidelines is warranted.
Authors: Thomas Marsland; Gerald Robbins; Alan Marks; Robert Cassell; Dorothy Green Philips; Kristen King Journal: J Oncol Pract Date: 2010-09 Impact factor: 3.840
Authors: Frederick P Rivara; Stephanie K Ennis; Rita Mangione-Smith; Ellen J MacKenzie; Kenneth M Jaffe Journal: Arch Phys Med Rehabil Date: 2012-01-26 Impact factor: 3.966
Authors: Peter A Walker; Phillip A Letourneau; Supinder Bedi; Shinil K Shah; Fernando Jimenez; Charles S Cox Journal: World J Stem Cells Date: 2011-02-26 Impact factor: 5.326
Authors: Latha Ganti; Aakash N Bodhit; Yasamin Daneshvar; Kelsey Hatchitt; Sudeep Kuchibhotla; Christa Pulvino; Sarah W Ayala; Keith R Peters Journal: World J Emerg Med Date: 2021
Authors: Peter A Walker; Matthew T Harting; Fernando Jimenez; Shinil K Shah; Shibani Pati; Pramod K Dash; Charles S Cox Journal: Stem Cells Dev Date: 2010-06 Impact factor: 3.272
Authors: Christina R Marmarou; Xiuyin Liang; Naqeeb H Abidi; Shanaz Parveen; Keisuke Taya; Scott C Henderson; Harold F Young; Aristotelis S Filippidis; Clive M Baumgarten Journal: Brain Res Date: 2014-06-13 Impact factor: 3.252
Authors: Peter A Walker; Matthew T Harting; Shinil K Shah; Mary-Clare Day; Ramy El Khoury; Sean I Savitz; James Baumgartner; Charles S Cox Journal: Stem Cells Int Date: 2010-07-20 Impact factor: 5.443